Ciclosporin to Reduce Reperfusion Injury in Primary PCI
Status:
Completed
Trial end date:
2017-11-11
Target enrollment:
Participant gender:
Summary
Routine primary percutaneous coronary intervention (PPCI) for a heart attack involves opening
a blocked artery with a balloon then inserting a metal scaffold (stent) to hold the artery
open. During this procedure inflammation can occur causing further damage to the heart. The
objective of this trial is to determine whether administration of the drug ciclosporin prior
to PPCI reduces the amount of damage to the heart relative to treatment with placebo. The
damage to the heart is assessed after 12 weeks by an magnetic resonance imaging (MRI) scan.
Patients are followed-up after 12 months participation in the study.
This is a single centre study looking to recruit 68 patients.
Phase:
Phase 2
Details
Lead Sponsor:
Newcastle-upon-Tyne Hospitals NHS Trust
Collaborators:
National Institute for Health Research, United Kingdom Newcastle University